Skip to main content

Table 1 Demographic information

From: Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment

Clinical pathological feature

Control (n = 30)

Tracer (n = 30)

Drug-load (n = 30)

Test value

P

Average age (year)

45.4 ± 7.8

47.1 ± 8.3

48.4 ± 9.8

0.885*

0.416

Tumor location

   

10.258#

0.247

 Upper outer quadrant

18

21

26

  

 Lower outer quadrant

5

3

0

  

 Upper inner quadrant

3

4

3

  

 Lower inner quadrant

1

0

1

  

 Central area

3

2

0

  

Clinical stage

   

2.018#

0.732

 I

8

8

6

  

 II

18

15

16

  

 IIIA

4

7

8

  

Pathological type

   

3.000#

0.558

 Infiltrating ductal carcinoma

29

29

29

  

 Mucinous carcinoma

1

1

0

  

 Medullary carcinoma

0

0

1

  

ER

   

1.348#

0.510

 Positive

19

20

23

  

 Negative

11

10

7

  

PR

   

0.098#

0.952

 Positive

20

19

20

  

 Negative

10

11

10

  

HER-2

   

4.229#

0.121

 Positive**

3

8

3

  

 Negative##

27

22

27

  

Surgical approach

   

4.488#

0.344

 Modified radical mastectomy

20

25

18

  

 Endoscopic subcutaneous mammary resection + axillary lymph nodes dissection + reconstruction with implants

9

4

11

  

 Breast-conserving surgery + axillary lymph nodes dissection

1

1

1

  
  1. ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, IHC immunohistochemistry
  2. *F value; #χ 2 value; **IHC (3+) in the first biopsy before surgery; ##IHC (0 ~ 2+) in the first biopsy before surgery